Flagship Pioneering Appoints Biotech Veteran Rahul Kakkar as CEO of Somatic Genomics Company Quotient Therapeutics
Key Insights
Flagship Pioneering (search) has appointed Rahul Kakkar (search), M.D., as CEO-Partner and CEO of Quotient Therapeutics (search), a company pioneering somatic genomics for drug discovery.
Dr. Kakkar brings nearly 20 years of biotech experience, including leadership roles at companies acquired for billions, such as Pandion Therapeutics (search) (acquired by Merck (search) for $1.85 billion) and Corvidia Therapeutics (search) (acquired by Novo Nordisk for $2.1 billion).
Quotient has developed the world's first industrial platform for discovering novel drug targets through somatic genomics and has established collaboration agreements with Pfizer in cardiovascular and renal diseases (search).
Flagship Pioneering (search) announced the appointment of Rahul Kakkar (search), M.D., as CEO-Partner and Chief Executive Officer of Quotient Therapeutics (search), a bioplatform company pioneering somatic genomics for drug discovery. The appointment marks a significant leadership transition for the company as it advances its novel approach to identifying drug targets through genetic variation analysis.
Proven Track Record in Biotech Leadership
Dr. Kakkar brings nearly 20 years of professional experience as a biotech entrepreneur and physician-scientist, with a demonstrated history of building successful biotechnology companies. Most recently, he served as President and CEO of Tome Biosciences (search), a genome engineering biotechnology platform company. His previous leadership roles include CEO positions at two companies that achieved billion-dollar acquisitions: Pandion Therapeutics (search), which was acquired by Merck (search) for $1.85 billion after completing an IPO, and Corvidia Therapeutics (search), which Novo Nordisk acquired for $2.1 billion.
Dr. Kakkar also served as Director of Emerging Innovations at AstraZeneca and continues to practice medicine at Brigham and Women's Hospital while serving as a lecturer in medicine at Harvard Medical School. He holds a B.A. from Tufts University and an M.D. from the Tufts University School of Medicine.
Somatic Genomics Platform and Strategic Partnerships
Under the leadership of co-founder Jake Rubens, Ph.D., Quotient developed what the company describes as the world's first industrial platform for discovering novel, human-validated drug targets via somatic genomics. The platform systematically studies genetic variation and evolution across the trillions of cells within the human body to reveal novel links between genes and disease across multiple therapeutic areas.
Quotient has established research sites in both the UK and US and has signed collaboration agreements with Pfizer focusing on cardiovascular and renal diseases (search). The company has validated and begun drug discovery against its first targets across multiple diseases and therapeutic areas.
Leadership Transition and Future Vision
Jake Rubens, who co-founded and led Quotient as CEO, will transition to a board director role while remaining involved in the company's growth. Noubar Afeyan, Ph.D., Co-founder of Quotient Therapeutics (search) and Founder and CEO of Flagship Pioneering (search), emphasized Dr. Kakkar's expertise in drug R&D and biotechnology platforms as valuable assets for Quotient's future development.
"The Human Genome Project opened incredible avenues twenty years ago for therapeutics development, creating hundreds of new medicines for patients," Dr. Kakkar stated. "Somatic genomics represents a similarly transformative step change, both in our understanding of disease biology and our ability as drug developers to create interventions."
Geoffrey von Maltzahn, Ph.D., Co-founder and Chairman of Quotient and General Partner at Flagship, highlighted Dr. Kakkar's track record of cultivating valuable pipelines and scaling companies at the frontiers of drug development domains.
About the Companies
Founded by Flagship Pioneering (search) in 2022, Quotient Therapeutics (search) focuses on discovering transformative medicines intended to cure, prevent, or reverse disease through its somatic genomics approach. Flagship Pioneering, operating with $14 billion of assets under management as of July 2024, has originated and fostered more than 100 scientific ventures since 2000, resulting in more than $60 billion in aggregate value. The current Flagship ecosystem comprises over 40 companies, including notable public companies such as Moderna, Sana Biotechnology, and Foghorn Therapeutics.